December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
A Comparison of Fixed Combination of Latanoprost and Timolol with Fixed Combination of Dorzolamide and Timolol (COSOPT) in Patients With Elevated Intraocular Pressure: A Three-month Masked Evaluator, Phase IIIb, Multicenter Study in the United States (XALCOM vs. COSOPT)
Author Affiliations & Notes
  • RM Feldman
    Ophthalmology Hermann University Eye Associates Houston TX
  • Footnotes
    Commercial Relationships    R.M. Feldman, Pharmacia F, C, R; Merck C, R. Grant Identification: Grant from Pharmacia
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 295. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      RM Feldman; A Comparison of Fixed Combination of Latanoprost and Timolol with Fixed Combination of Dorzolamide and Timolol (COSOPT) in Patients With Elevated Intraocular Pressure: A Three-month Masked Evaluator, Phase IIIb, Multicenter Study in the United States (XALCOM vs. COSOPT) . Invest. Ophthalmol. Vis. Sci. 2002;43(13):295.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Reducing intraocular pressure slows progression of glaucomatous optic neuropathy and control of IOP remains the principal goal of glaucoma treatment. Satisfactory control is not always achieved with monotherapy. Fixed combinations provide advantages in compliance, efficacy and reduced side effects. The primary objective of this study was to compare the IOP lowering efficacy of a fixed combination of latanoprost 0.005% and timolol 0.5% (Xalcom) QD to a fixed combination of dorzolamide 2% and timolol 0.5% (Cosopt) BID in patients with elevated IOP. Methods: 251 patients with uni or bilateral primary open angle glaucoma or ocular hypertension received either Xalcom once daily or Cosopt twice daily in a three month multicenter, randomized, parallel group, investigator masked study. The primary efficacy variable was mean change in diurnal IOP from baseline at month 3 analyzed using ANCOVA, baseline diurnal IOP as covariate and treatment and center as independent variables. Results: Both Xalcom and Cosopt produced statistically significant reductions in baseline mean diurnal IOP (P < 0.0001). The adjusted mean IOP reductions were 8.4 mm Hg for Cosopt and 9.4 mm Hg for Xalcom (P < 0.025). The frequency of adverse events was similar between the two groups. Conclusions: Once daily Xalcom is significantly more efficacious in lowering IOP than twice daily Cosopt in patients with primary open angle glaucoma or ocular hypertension.

Keywords: 444 intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×